19:05 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

Fauci details goals of new Ebola trial

The first randomized, controlled trial of potential Ebola therapies conducted during an outbreak has started enrolling patients in the Democratic Republic of Congo. The trial is intended to treat patients who are affected by an...
17:05 , Aug 23, 2018 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Biosynthesis An E. coli -based method could be used to produce glycosylated versions of proteins as therapies and vaccine components. The method involves three steps: engineering E. coli with plasmids that express components of...
19:21 , Jun 20, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A method utilizing click chemistry to generate injectable hydrogels containing cross-linked cells could be used in regenerative therapies. The method generates hydrogels containing cross-linked cells in three steps: metabolic incorporation of azide...
15:30 , Jun 8, 2018 |  BC Week In Review  |  Company News

DRC approves compassionate use of investigational Ebola treatments

A Democratic Republic of the Congo ethics committee approved the use of five investigational Ebola therapies under compassionate use and expanded access. The World Health Organization said four of the five approved products are in...
21:03 , Jun 6, 2018 |  BC Extra  |  Company News

DRC approves investigational Ebola treatments

A Democratic Republic of the Congo ethics committee approved the use of five investigational Ebola therapies under compassionate use and expanded access. The World Health Organization said four of the five approved products are in...
23:43 , May 31, 2018 |  BC Extra  |  Company News

Regeneron sends experimental Ebola therapy to Congo

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said it began shipping its investigational Ebola antibody cocktail REGN-EB3 (REGN3470-3471-3479) to the Democratic Republic of the Congo (DRC). REGN-EB3 was one of several experimental therapies considered for the treatment of...
18:23 , May 25, 2018 |  BC Week In Review  |  Company News

WHO to start treatment with Merck's Ebola vaccine

The World Health Organization began administering Ebola vaccine rVSV-ZEBOV (V920) from Merck & Co. Inc. (NYSE:MRK) on May 21 in two cities in the Democratic Republic of the Congo (DRC). Vaccination will be administered using...
23:03 , May 18, 2018 |  BC Extra  |  Politics & Policy

WHO: Congo may approve mAb Zmapp for Ebola outbreak

The Democratic Republic of the Congo is likely to approve the use of Zmapp “in the coming days” to treat patients affected by the country's Ebola outbreak, the World Health Organization said Friday. President Larry...
18:32 , May 15, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Binding assays; cellular assays A click chemistry-based method for identifying cell surface glycoproteins that bind orphan ligands could help identify new therapeutic targets. The method involves three steps: mildly oxidizing live cells to produce...
15:04 , Apr 9, 2018 |  BC Extra  |  Preclinical News

Targeting neuraminidase could improve flu vaccine

A paper in Cell proposes a new strategy to develop an influenza vaccine exploiting the less targeted surface glycoprotein neuraminidase. Efforts to produce effective influenza vaccines have mainly focused on inhibiting hemagglutinin, the more abundant...